| Revenue growth | FY26 13.5% YoY; Q4 14.6% YoY. |
|---|---|
| Margins | FY26 EBITDA margin at 20.4%; guided 20-21% for FY27. |
| Demand visibility | Strong traction in chronic segments and international markets. |
| Management confidence | High; citing landmark year and successful new launches. |
Growth
Q4 revenue grew 14.6% YoY to INR 36,033m. FY26 revenue at INR 147,123m (up 13.5%) with 20.4% EBITDA margins.
Outlook
Targets 100-150 bps outperformance over Indian Pharma Market growth. FY27 EBITDA margins guided between 20-21%.
Risks
Geopolitical instability, increased logistics costs, and pricing pressure on APIs and packaging materials.
Earnings Call filed with BSE, NSE: ALKEM. Summary written with AI assistance from the document.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,350.50
- Market cap
- ₹63,973 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.6×Sector 47.3×
- Promoter holding
- 49.70%-1.50% QoQ
- FII holding
- 10.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories Management Change
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.
Alkem Laboratories Product Launch
Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.
Alkem Laboratories Annual General Meeting
Alkem Laboratories Limited concluded its 52nd Annual General Meeting on August 27, 2026. All resolutions proposed in the notice were duly approved by the members.